# A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients

> **NCT02649218** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 226 (actual)

## Conditions studied

- Chronic Spontaneous Urticaria

## Interventions

- **BIOLOGICAL:** Ligelizumab

## Key facts

- **NCT ID:** NCT02649218
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-24
- **Primary completion:** 2019-05-02
- **Final completion:** 2019-05-02
- **Target enrollment:** 226 (ACTUAL)
- **Last updated:** 2021-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02649218

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02649218, "A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02649218. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*